Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years

Authors:
  • P(Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
    Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
  • DCDominique Costagliola
    Dominique Costagliola
  • PRPeter Reiss
    Peter Reiss
  • CTCarlo Torti
    Carlo Torti
  • RTRamón Teira
    Ramón Teira
  • BLBruno Ledergerber
    Bruno Ledergerber
  • AMAmanda Mocroft
    Amanda Mocroft
  • DPDaniel Podzamczer
    Daniel Podzamczer
  • ACAlessandro Cozzi-Lepri
    Alessandro Cozzi-Lepri
  • NONiels Obel
    Niels Obel

Abstract
Life expectancy and, equivalently, age-specific death rates in people with HIV have been estimated to be approaching those of the uninfected general population in some successfully treated subgroups.1,2 These promising life expectancies will only be realized, however, if death rates associated with HIV do not rise in the future. The main underlying mechanism by which rates have been reduced is complete suppression of viral replication by antiretroviral therapy (ART), and so low death rates are dependent on the duration of continued viral suppression. Most regimens used so far contain drugs from the original 3 ART classes: nucleos(t)ide reverse-transcriptase inhibitors (NRTIs), nonNRTIs (NNRTIs), and protease inhibitors (PIs). Current regimens tend to lead to sustained viral suppression in most patients, but rates of virologic failure (failure to [continue to] suppress viral load) remain appreciable. Virologic failure is thought to occur as the result of an uncertain mixture between suboptimal regimen adherence and the development of resistance. The fact that some patients are infected with resistant virus is probably an additional cause. So, while multiple drugs from several new classes are now available (integrase inhibitors, fusion inhibitors, and chemokine [C-C motif] receptor 5 [CCR5] antagonists), at least in high-income countries, lifelong viral suppression and consequential low death rates cannot be assured indefinitely. Virologic failure of the 3 original classes represents a key stage in a patient's drug failure history, and it is important to monitor the rate with which this is occurring to anticipate the continuing need for new drugs.3-12 Such prediction of future need is important in the light of the lengthy drug development process.

This publication has 28 references indexed in Scilit: